Imai S, Kiyozuka Y, Nishimura H, Iwanaga S, Murakami F, Imamura K, Noda T, Haga S, Yakushiji M
KURUME UNIV,SCH MED,DEPT OBSTET & GYNECOL,KURUME,FUKUOKA 830,JAPAN. HIGASHI OSAKA CENT HOSP,DEPT OBSTET & GYNECOL,OSAKA,OSAKA,JAPAN. NARA MED UNIV,DEPT ANAT 2,KASHIHARA,NARA,JAPAN.
Int J Oncol. 1994 May;4(5):1097-103. doi: 10.3892/ijo.4.5.1097.
An extensive series of histological sections from various types of benign, borderline, and malignant human ovarian tumors were examined for expression of the p53 protein by immunohistochemical staining, using a new anti-p53 mouse monoclonal antibody. Positive staining for p53 was detected in 34% of all malignant ovarian cancer tissues. A high rate of positivity was observed in serous cystadenocarcinoma (59.7%). None of the borderline or benign tumors showed any reaction. No relation was observed between clinical stage, and the frequency of p53 positivity. Mutation of the p53 gene with overexpression of the mutant protein appears to be a specific genetic change in human ovarian cancer.
使用一种新型抗p53小鼠单克隆抗体,通过免疫组织化学染色检查了来自各种类型的良性、交界性和恶性人类卵巢肿瘤的一系列广泛组织学切片中p53蛋白的表达情况。在所有恶性卵巢癌组织中,34%检测到p53阳性染色。浆液性囊腺癌中的阳性率较高(59.7%)。交界性或良性肿瘤均未显示任何反应。未观察到临床分期与p53阳性频率之间的关系。p53基因的突变与突变蛋白的过表达似乎是人类卵巢癌中的一种特异性基因变化。